Breaking News Instant updates and real-time market news.

AAPL

Apple

$160.82

-0.68 (-0.42%)

, GS

Goldman Sachs

$225.95

4.89 (2.21%)

16:20
09/12/17
09/12
16:20
09/12/17
16:20

On The Fly: Top stock stories for Tuesday

Stocks opened in positive territory and remained there for most of the session. The averages moved in a very narrow range as investors awaited and then focused on the new product presentation from Apple (AAPL). Shares of Apple were up as much as 2% early in the event, but fell, as is often the case with these events, as the presentation headed to a close. Despite the swing in Apple shares, the market held its gains, building on yesterday's rally. ECONOMIC EVENTS: In the U.S., the JOLTS report showed job openings rose 54,000 to 6.17M in July, hitting a new record high. In Europe, U.K. inflation accelerated to 2.9% in August, which was more than economists had expected. COMPANY NEWS: Apple shares finished the day fractionally lower at $160.82 following the tech giant's keynote event, during which it premiered several new iPhone models as well as the next version of its Apple Watch. While the tech giant announced the next standard editions of its smartphone, namely the iPhone 8 and 8 Plus, the announcement of the iPhone X stole the show. The X, pronounced "ten," will serve as a premium edition of the iPhone with a 5.8-inch Super Retina display, wireless charging, and the ability to unlock, authenticate and pay using facial identification. The device, priced starting at $999, will be available on November 3, meaning that sales will be pushed into Apple's next fiscal year. The company also unveiled the Apple TV 4K as well as the Apple Watch Series 3, which will add built-in cellular capabilities to the wearable device... Meanwhile, shares of several big banks rose following their presentations at the Barclays financial services conference. Goldman Sachs (GS) shares rose over 2% after co-COO Harvey Schwartz said at the event that the firm sees $5B in revenue growth opportunities over the next three years, while shares of Wells Fargo (WFC) were almost 2% higher after guiding for 2017 net interest income growth in the low to mid single digits. Meanwhile, Bank of America (BAC) and JPMorgan (JPM) also gained, despite the banks pointing to potential year-over-year declines of 15% and 20%, respectively, in their third quarter trading revenues. MAJOR MOVERS: Among the noteworthy gainers was Inovalon (INOV), which advanced 17% after the stock was upgraded to Equal Weight from Underweight at Morgan Stanley. Also higher was Gap (GPS), which gained more than 6% after Jefferies analyst Randal Konik raised his price target on the stock to $39 and added the shares to his firm's Franchise Pick list, citing Old Navy's potential and the company's allocation of capital to support its growth. Among the notable losers was Intercept Pharmaceuticals (ICPT), which fell over 13% after the company sent a letter to health care providers highlighting the fact that liver injury, liver decompensation, liver failure, and death have been reported in primary biliary cholangitis patients with moderate or severe hepatic impairment when Ocaliva was dosed more frequently than recommended. Also lower was Sage Therapeutics (SAGE), which dropped more than 13% after the company's Phase 3 trial of brexanolone in Super Refractory Status Epilepticus, or SRSE, failed to meet its primary and secondary endpoints. INDEXES: The Dow rose 61.49, or 0.28%, to 22,118.86, the Nasdaq gained 22.02, or 0.34%, to 6,454.28, and the S&P 500 advanced 8.37, or 0.34%, to 2,496.48.

AAPL

Apple

$160.82

-0.68 (-0.42%)

GS

Goldman Sachs

$225.95

4.89 (2.21%)

WFC

Wells Fargo

$51.57

0.91 (1.80%)

BAC

Bank of America

$23.95

0.59 (2.53%)

JPM

JPMorgan

$90.89

1.1 (1.23%)

INOV

Inovalon

$17.10

2.45 (16.72%)

GPS

Gap

$27.61

1.67 (6.44%)

SAGE

Sage Therapeutics

$76.40

-12.12 (-13.69%)

ICPT

Intercept

$98.12

-15.36 (-13.54%)

  • 12

    Sep

  • 12

    Sep

  • 12

    Sep

  • 12

    Sep

  • 18

    Sep

  • 12

    Oct

  • 13

    Oct

  • 17

    Oct

  • 29

    Nov

  • 12

    Jan

  • 27

    Feb

  • 13

    Apr

  • 14

    Jul

  • 12

    Oct

AAPL Apple
$160.82

-0.68 (-0.42%)

09/12/17
JPMS
09/12/17
NO CHANGE
JPMS
JPMorgan lays out iPhone content winners and losers into launch event
JPMorgan analyst Harlan Sur believes Apple's (AAPL) launch event today will be positive for Broadcom (AVGO) and Qorvo (QRVO) as well as Micron (MU) and Intel (INTC). The analyst sees content gains by Broadcom in wireless charging, touch controller, Wi-Fi/Bluetooth and GPS connectivity, and by Qorvo in low band power amplifier duplexers share and antenna tuning. Other companies with significant Apple exposure that would benefit from increased unit sales and/or modest content gains include Intel, Skyworks (SWKS), Knowles (KN), Micron, Cypress Semiconductor (CY), NXP Semiconductors (NXPI) and Texas Instruments (TXN), Sur tells investors in a research note. The analyst sees Analog Devices' (ADI) blended content at Apple declining as he believes the company will not be the touch controller for the OLED-version of the iPhone.
09/12/17
BERN
09/12/17
NO CHANGE
BERN
Apple iPhone supply chain may be under pressure, says Bernstein
Ahead of today's Apple event, Bernstein analyst David Dai says he believes share prices of iPhone supply chain may be under pressure in the next 1-3 months and suggests investors to switch from iPhone supply chain companies to non-Apple suppliers to position themselves toward the iPhone launch. Additionally, the analyst says he does not expect major surprises from Apple's event.
09/12/17
JPMS
09/12/17
NO CHANGE
Target $315
JPMS
Overweight
JPMorgan still confident Apple will integrate Broadcom's wireless charging
Ahead of today's next generation iPhone announcement, JPMorgan analyst Harlan Sur says he remains confident that Apple (AAPL) will integrate Broadcom's (AGO) wireless charging chip into the next iPhone family in the second half of 2017. Broadcom commenced manufacturing production of the chip back in late June with its foundry partners, Sur tells investors in a research note. The analyst is also confident that Apple will also use Broadcom's next generation Wi-Fi/Bluetooth combo chip which enables simultaneous Wi-Fi data transmit/receive on both 2.4Ghz/5Ghz bands and the new Bluetooth 5.0 standard. He sees at least a $3-$4 step-up, or 40%-45% increase, in dollar content for Broadcom in the new iPhone relative to last year's models. Sur reiterates an Overweight rating on Broadcom with a $315 price target.
09/12/17
PIPR
09/12/17
NO CHANGE
Target $190
PIPR
Overweight
Apple 'met lofty expectations' for iPhone X upgrades, says Piper Jaffray
Piper Jaffray analyst Michael Olson said the features of Apple's iPhone X "generally met" the "lofty expectations" set by media reports prior to the company's product launch event today, pointing to its edge-to-edge OLED screen and 3D sensing as the key upgrades. Apple's prior commentary suggests this cycle will see a higher upgrade rate than previous iPhones, added Olson, who keeps an Overweight rating and $190 price target on Apple shares.
GS Goldman Sachs
$225.95

4.89 (2.21%)

08/11/17
HSBC
08/11/17
DOWNGRADE
HSBC
Hold
Goldman Sachs downgraded to Hold from Buy at HSBC
07/24/17
07/24/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Goldman Sachs (GS) downgraded to Neutral from Buy at UBS with analyst Brennan Hawken saying the market seems to be pricing in an inflection in Goldman's trading revenue despite the recent weakness, suggesting a recovery is needed to justify 2018 consensus estimates. 2. Constellation Brands (STZ) downgraded to Neutral from Conviction Buy at Goldman Sachs. 3. Boston Beer (SAM) downgraded to Sell from Neutral at Goldman Sachs with analyst Judy Hong saying she sees further downside risk from weaker volumes and believes 2018 will be another year of volume decline and limited margin offset. 4. athenahealth (ATHN) downgraded to Underweight from Equal-Weight at First Analysis with analyst Frank Sparacino saying the valuation at current share levels is ahead of the underlying fundamentals in the short term. 5. PPG (PPG) was downgraded to Hold from Buy at SunTrust and to Neutral from Buy at BofA/Merrill. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
09/12/17
KBWI
09/12/17
NO CHANGE
KBWI
Market Perform
Keefe Bruyette 'somewhat skeptical' of Goldman Sachs revenue targets
Keefe Bruyette analyst Brian Kleinhanzl noted that Goldman Sachs co-COO Harvey Schwartz identified $5B in revenue opportunities that the company sees over the next 3 years, though he is "somewhat skeptical" of the bank's ability to hit these targets given that its strategy requires penetrating new markets or segments outside of its traditional strengths. The analyst, who thinks Goldman remains a "show-me stock," keeps a Market Perform rating on the shares.
08/09/17
WELS
08/09/17
INITIATION
Target $265
WELS
Outperform
Goldman Sachs resumed with an Outperform at Wells Fargo
Wells Fargo analyst Mike Mayo resumed coverage of Goldman Sachs (GS) with an Outperform rating and $265 price target. The analyst prefers Goldman over Morgan Stanley (MS), saying the bank has about "twice as fast" organic revenue growth for more than 20 years, and "much faster" earnings growth over 15 years. Mayo named Citi (C) his top pick among the Large-Cap banks.
WFC Wells Fargo
$51.57

0.91 (1.80%)

07/31/17
BMOC
07/31/17
UPGRADE
BMOC
Market Perform
Wells Fargo upgraded to Market Perform from Underperform at BMO Capital
07/31/17
07/31/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Altria Group (MO) upgraded to Sector Perform from Underperform at RBC Capital with analyst Nik Modi saying he believes the FDA's tobacco announcement on Friday was "very much in line" with industry expectations despite the surprise to investors. 2. American Airlines (AAL) upgraded to Outperform from Market Perform at Cowen. 3. Baidu (BIDU) upgraded to Buy from Neutral at Nomura Instinet with analyst Jialong Shi-NIHK citing accelerating revenue momentum driven by news feed ads and an undervalued video business. 4. Wells Fargo (WFC) upgraded to Market Perform from Underperform at BMO Capital with analyst James Fotheringham citing valuation. The firm also ended its pair trade call of going long Citi (C) and short Wells Fargo. 5. GoPro (GPRO) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Yuuji Anderson saying valuation better reflects efforts to driver better product cycles through software improvements. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
07/31/17
BMOC
07/31/17
DOWNGRADE
BMOC
Market Perform
Citi downgraded on valuation, lack of catalysts at BMO Capital
As noted earlier, BMO Capital downgraded Citi (C) to Market Perform from Outperform. Analyst James Fotheringham downgraded the stock based on valuation and lack of catalysts. In conjunction with this note, he upgraded Wells Fargo (WFC) to Outperform from Market Perform and ended his pair trade call of going long Citi and short Wells Fargo. Target on Citi is $65.
07/31/17
BMOC
07/31/17
UPGRADE
BMOC
Market Perform
Wells Fargo upgraded on valuation at BMO Capital
As noted earlier, BMO Capital upgraded Wells Fargo (WFC) to Market Perform from Underperform. Analyst JamesFotheringham upgraded the stock based on valuation. In conjunction with the note, the firm downgraded Citi (C) to Market Perform from Outperform, and ended its pair trade call of going long Citi and short Wells Fargo. Target on Wells Fargo is $49.
BAC Bank of America
$23.95

0.59 (2.53%)

06/09/17
RBCM
06/09/17
NO CHANGE
RBCM
House financial reform bill unlikely to advance in Senate, says RBC Capital
RBC Capital analyst Gerard Cassidy says that the financial regulation reform bill passed yesterday by the House would help the banking sector but probably won;t be passed by the Senate. Large publicly traded banks include Bank of America (BAC), Citi (C), Goldman Sachs (GS), JPMorgan (JPM), Morgan Stanley (MS), U.S. Bancorp (USB) and Wells Fargo (WFC).
07/11/17
BARD
07/11/17
NO CHANGE
BARD
Big bank set-up not great, would sell into extended rally, says Baird
Baird analyst David George does not see a great set-up for money-center banks heading into Q2 earnings. He said the trade looks crowded and he would be a seller into an extended rally. George said the risk/reward is less attractive following the sector's most recent rally as economic growth remains muted and the pace of NIM expansion may slow. George believes the biggest potential catalyst would be a gradual steepening of the yield curve and pick-up on loan growth.
07/18/17
NOMU
07/18/17
NO CHANGE
Target $27
NOMU
Buy
Bank of America NII softness could weight on shares, says Nomura Instinet
Nomura Instinet analyst Steven Chubak said Bank of America reported a modest core beat but the NII miss and elevated bar for Q3 could result in modest share underperformance. The analyst remains encouraged by fee income resiliency, favorable credit trends, strong capital build, and compelling risk/reward, and reiterates his Buy rating and $27 price target.
08/09/17
WELS
08/09/17
INITIATION
WELS
Outperform
Bank of America resumed with an Outperform at Wells Fargo
Wells Fargo analyst Mike Mayo resumed coverage of Bank of America with an Outperform rating and $30 price target.
JPM JPMorgan
$90.89

1.1 (1.23%)

07/06/17
07/06/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Nike (NKE) initiated with an Outperform at Raymond James. 2. JPMorgan (JPM) initiated with a Neutral at Goldman Sachs. 3. At Home Group (HOME) initiated with a Buy at SunTrust. 4. Logitech (LOGI) initiated with a Buy at Citi. 5. Medtronic (MDT) initiated with an Outperform at William Blair. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/06/17
GSCO
07/06/17
INITIATION
Target $93
GSCO
Neutral
JPMorgan initiated with a Neutral at Goldman Sachs
Goldman analyst Richard Ramsden resumed coverage on JPMorgan with a Neutral and a $93 price target saying it is a best-in-class franchise with a premium multiple.
08/09/17
WELS
08/09/17
INITIATION
Target $110
WELS
Outperform
JPMorgan resumed with an Outperform at Wells Fargo
Wells Fargo analyst Mike Mayo resumed coverage JPMorgan with an Outperform rating and $110 price target.
INOV Inovalon
$17.10

2.45 (16.72%)

09/12/17
09/12/17
UPGRADE
Target $14

Equal Weight
Inovalon upgraded to Equal Weight on better visibility at Morgan Stanley
As previously reported, Morgan Stanley analyst Ricky Goldwasser upgraded Inovalon to Equal Weight from Underweight, stating that the company's presentation at the firm's healthcare conference provided a line of sight to organic earnings acceleration in the second half of the year. The analyst, who notes that headwinds from the transition to per member per month pricing are now being lapped, raised his 2017 estimates for Inovalon and increased his price target on the stock to $14 from $9.
09/12/17
MSCO
09/12/17
UPGRADE
MSCO
Equal Weight
Inovalon upgraded to Equal Weight from Underweight at Morgan Stanley
09/12/17
09/12/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Comerica (CMA) upgraded to Overweight from Neutral at Piper Jaffray with analyst Brett Rabatin saying the bank's mid-quarter update is better than expected. 2. Alcoa (AA) upgraded to Buy from Hold at Deutsche Bank with analyst Jorge Beristain basing the upgrade on the firm's commodity team raising its 2018 aluminum price forecast by 12% to $2,072 per ton. 3. Kroger (KR) upgraded to Buy from Hold at Pivotal Research with analyst Ajay Jain saying continued weakness in investor sentiment following Kroger's latest results presents a near-term buying opportunity. 4. Comcast (CMCSA) upgraded to Buy from Neutral at MoffettNathanson with analyst Craig Moffett saying Comcast shares cheap following management comments on third quarter subscriber loses and the resulting stock selloff is overdone. 5. Inovalon (INOV) upgraded to Equal Weight from Underweight at Morgan Stanley with analyst Ricky Goldwasser saying that the company's presentation at the firm's healthcare conference provided a line of sight to organic earnings acceleration in the second half of the year. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
02/23/17
PIPR
02/23/17
NO CHANGE
Target $7
PIPR
Underweight
Piper views Inovalon outlook as 'overly optimistic'
Piper Jaffray analyst Sean Wieland lowered his price target for Inovalon shares to $7 from $8 saying the company's 2017 outlook is "overly optimistic." Inovalon provided little detail on how it will go from an 18% revenue decline in the second half of 2016 to down 11% in the first half of 2017 to up 11% in the second half of the year, Wieland tells investors in a research note. While management said the whistleblower lawsuit unsealed last week against United alleging systemic Medicare Advantage fraud is without merit, the analyst expects the suit to change the risk adjustment landscape and drive greater insourcing of the function, which he thinks will likely pressure renewal rates. Wieland keeps an Underweight rating on Inovalon.
GPS Gap
$27.61

1.67 (6.44%)

09/01/17
SBSH
09/01/17
UPGRADE
Target $24
SBSH
Neutral
Gap upgraded to Neutral from Sell at Citi
Citi analyst Paul Lejuez upgraded Gap to Neutral citing low expectations and support from the 4% dividend yield. Concerns of a slowdown at Old Navy appear more priced in at current valuation levels, Lejuez tells investors in a research note. He raised his price target for the shares to $24 from $22. Gap closed yesterday up 14c to $23.62.
09/12/17
JEFF
09/12/17
NO CHANGE
Target $39
JEFF
Buy
Jefferies ups Gap target to $39, adds to Franchise Pick list
Jefferies analyst Randal Konik raised his price target for Gap to $39 from $35 adds the shares to his firm's Franchise Pick list. The analyst notes his sum-of-the-parts analysis implies 50%-plus upside to the current share price. Investment changes will drive improved stability and stronger free cash flow, which should lead to upward earnings and multiple expansion, Konik tells investors in a research note. He keeps a Buy rating on Gap shares.
09/06/17
JEFF
09/06/17
NO CHANGE
Target $35
JEFF
Buy
Gap taking right steps for the long-term, says Jefferies
Jefferies analyst Randal Konik says Gap's investor presentation today shows the retailer is taking the right steps to position its business for the long-term. In an intraday research note titled "A Presentation for the Ages...How You Get It Done Right!," Konik writes that he believes the $10B revenue target laid out for Old Navy underscores the ongoing momentum at the brand. He reiterates a Buy rating on Gap shares with a $35 price target.
09/01/17
09/01/17
UPGRADE

On The Fly: Top five analyst upgrades
Catch up on today's top five analyst upgrades with this list compiled by The Fly: 1. Palo Alto Networks (PANW) was upgraded to Overweight from Neutral at JPMorgan and to Overweight from Equal-Weight at First Analysis. 2. Gap (GPS) upgraded to Neutral from Sell at Citi, with analyst Paul Lejuez saying concerns of a slowdown at Old Navy appear more priced in at current valuation levels. He raised his price target for the shares to $24 from $22. 3. Gerdau (GGB) upgraded to Overweight from Neutral at JPMorgan with analyst Rodolfo Angele saying the company's business environment has improved. 4. Owens & Minor (OMI) upgraded to Neutral from Underperform at Baird with analyst Eric Coldwell citing its relative underperformance. 5. Toronto-Dominion (TD) upgraded to Outperform from Sector Perform at National Bank. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
SAGE Sage Therapeutics
$76.40

-12.12 (-13.69%)

09/12/17
BMOC
09/12/17
NO CHANGE
Target $84
BMOC
Outperform
Focus shifting to PPD data as Sage SRSE study disappoints, says BMO Capital
BMO Capital analyst Gary Nachman notes that Sage Therapeutics reported disappointing Phase 3 results for brexanolone in SRSE, and will not move forward with it. Additionally, the analyst points out that management remains just as confident with upcoming Phase 3 data for brexanolone in postpartum depression and Phase 2b data for SAGE-217 in MDD, both in 2H17, as it does not see read-through to those from SRSE. While the SRSE data is a clear setback, most view PPD/MDD as the more exciting opportunities longer term, which provides a support level for the stock, Nachman adds. He reiterates an Outperform rating and $84 price target on the shares.
09/12/17
JPMS
09/12/17
NO CHANGE
Target $85
JPMS
Overweight
Sage Therapeutics price target lowered to $85 from $99 at JPMorgan
JPMorgan analyst Cory Kasimov lowered his price target for Sage Therapeutics to $85 after zeroing out super refractory status epilepticus due to this morning's Phase 3 failure. The analyst keeps an Overweight rating on the shares, however, saying he still has higher conviction in the Phase 2 and 3 postpartum depression programs. The stock's resiliency today highlights the value in having a broad pipeline, Kasimov writes in an intraday research note. Sage in afternoon trading is down 15%, or $13.70, to $74.82.
09/12/17
ADAM
09/12/17
NO CHANGE
Target $81
ADAM
Buy
Sage Therapeutics price target lowered to $81 from $110 at Canaccord
Canaccord Genuity analyst John Newman lowered his price target for Sage Therapeutics to $81 after SAGE-547 missed the primary endpoint in the Phase 3 Status trial. The analyst, however, is not concerned on read-through to other indications. The mechanism of action for SAGE-547 and SAGE-217 is still valid, Newman tells investors in a research note. After removing super refractory status epilepticus from his model, the analyst keeps a Buy rating on Sage.
09/12/17
COWN
09/12/17
NO CHANGE
Target $90
COWN
Outperform
Sage Therapeutics price target lowered to $90 from $100 at Cowen
Cowen analyst Ritu Baral lowered her price target for Sage Therapeutics to $90 after Phase 3 Status trial of brexanolone failed to meet primary and secondary endpoints. The analyst viewed super refractory status epilepticus as the highest-risk indication in Sage's pipeline. With multiple depression catalysts in the second half of 2017, incremental buyers are likely to step into the shares on today's weakness, Baral tells investors in a research note. The analyst keeps an Outperform rating on Sage.
ICPT Intercept
$98.12

-15.36 (-13.54%)

09/12/17
BARD
09/12/17
NO CHANGE
Target $332
BARD
Outperform
Baird would buy Intercept on weakness
Baird analyst Brian Skorney recommends buying Intercept shares on weakness related to the "Dear Healthcare Provider Letter." The analyst said there is no new information in the letter and serves as a reminder to modify does according to the label for patients with hepatic impairment following cases of Ocaliva being dosed more frequently than recommended. Skorny rates Intercept an Outperform with a $332 price target.
09/12/17
JEFF
09/12/17
NO CHANGE
JEFF
Intercept selloff an 'overreaction,' says Jefferies
Jefferies analyst Michael Yee said the sell off in Intercept shares is an "overreaction" to the "Dear Healthcare Provider Letter" and said the risk/benefit of OCA remains favorable. The analyst said there is no change to his Buy thesis and $275 price target and would be buyers of the stock and expects shares to recover as the Phase III trial in cirrhotic patients is initiated by year-end and as we approach Phase III NASH results in early 2019.
09/12/17
CANT
09/12/17
NO CHANGE
Target $69
CANT
Underweight
Cantor reiterates $69 target on Intercept after Ocaliva warning letter
Cantor Fitzgerald analyst Elemer Piros reiterates an Underweight rating on Intercept Pharmaceuticals after the company sent a letter to healthcare providers warning that serious liver injuries, including death, have been reported in liver-impaired primary biliary cholangitis patients dosed with Ocaliva at higher than recommended levels. The news raises caution on the PBC franchise's future growth potential in more severe patients, and signals a "potential hurdle" for further penetration, Piros tells investors in a research note. Intercept in early trading is down 19% to $92.08.
09/12/17
SBSH
09/12/17
NO CHANGE
Target $240
SBSH
Buy
Intercept patient safety letter a 'meaningful negative,' says Citi
Citi analyst Joel Beatty calls Intercept Pharmaceuticals' patient safety letter a "meaningful negative" for Intercept Pharmaceuticals. The letter could "dampen physician enthusiasm" to prescribe Ocaliva in primary biliary cholangitis, especially if other competing agents are approved, Beatty tells investors in a research note. He also believes the news is likely to raise investor concerns about the safety of obeticholic acid in nonalcoholic steatohepatitis. The analyst notes that Intercept, when asked, see no impact on the Phase 3 Regenerate trial of OCA in NASH. Intercept in early trading is down 20%, or $22.34, to $91.14. Beatty keeps a Buy rating on the shares with a $240 price target. He notes his price target is largely based on NASH.

TODAY'S FREE FLY STORIES

MMS

Maximus

$71.42

-0.47 (-0.65%)

16:04
01/16/18
01/16
16:04
01/16/18
16:04
Hot Stocks
Maximus appoints Bruce Caswell as CEO after retirement of Richard Montoni »

Maximus announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HTGM

HTG Molecular

$3.50

-0.14 (-3.85%)

16:04
01/16/18
01/16
16:04
01/16/18
16:04
Syndicate
HTG Molecular files to sell $10M shares of common stock »

Leerink Partners LLC and…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

OBLN

Obalon Therapeutics

$7.93

0.03 (0.38%)

16:03
01/16/18
01/16
16:03
01/16/18
16:03
Syndicate
Obalon Therapeutics files to sell $35M on common stock »

UBS Investment Bank,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

NTNX

Nutanix

$36.01

-1.83 (-4.84%)

16:03
01/16/18
01/16
16:03
01/16/18
16:03
Syndicate
Breaking Syndicate news story on Nutanix »

Nutanix files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

UAA

Under Armour; also tag UA

$13.63

-1.49 (-9.85%)

15:55
01/16/18
01/16
15:55
01/16/18
15:55
Options
Under Armour Class A put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

15:55
01/16/18
01/16
15:55
01/16/18
15:55
General news
Treasury Closing Summary: »

Treasury Closing Summary:…

LVS

Las Vegas Sands

$72.58

1.56 (2.20%)

15:52
01/16/18
01/16
15:52
01/16/18
15:52
Periodicals
Breaking Periodicals news story on Las Vegas Sands »

Las Vegas Sands added as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

HMST

HomeStreet

$32.35

1 (3.19%)

15:48
01/16/18
01/16
15:48
01/16/18
15:48
Hot Stocks
HomeStreet raises company-wide minimum wage to $15 per hour »

HomeStreet announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

HUM

Humana

$270.41

2.39 (0.89%)

15:45
01/16/18
01/16
15:45
01/16/18
15:45
Options
Humana call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Feb

USB

U.S. Bancorp

$57.46

0.48 (0.84%)

15:45
01/16/18
01/16
15:45
01/16/18
15:45
Hot Stocks
U.S. Bancorp names CEO Andy Cecere chairman of the board »

U.S. Bancorp, parent…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

LADR

Ladder Capital

$14.53

0.94 (6.92%)

15:39
01/16/18
01/16
15:39
01/16/18
15:39
Upgrade
Ladder Capital rating change  »

Ladder Capital upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jan

  • 31

    Jan

  • 01

    Feb

ONCE

Spark Therapeutics

$52.66

-1.41 (-2.61%)

15:30
01/16/18
01/16
15:30
01/16/18
15:30
Hot Stocks
Spark Therapeutics treatment of hemophilia A granted FDA orphan status »

Spark Therapeutics'…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Feb

PX

Praxair

$161.26

-2.89 (-1.76%)

15:30
01/16/18
01/16
15:30
01/16/18
15:30
Options
$6M option print in Praxair as shares deflate »

$6M option print in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CGI

Celadon Group

$6.20

-0.4 (-6.06%)

15:26
01/16/18
01/16
15:26
01/16/18
15:26
Periodicals
Celadon Group mentioned cautiously again by Prescience Point 

Reference Link

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RGSE

RGS Energy

15:24
01/16/18
01/16
15:24
01/16/18
15:24
Hot Stocks
Iroquois Capital reports 6.3% stake in Real Goods Solar »

This activist stake held…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MGM

MGM Resorts

$36.09

1.06 (3.03%)

15:20
01/16/18
01/16
15:20
01/16/18
15:20
Options
Notable spread in MGM as shares rally »

Notable spread in MGM as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NSD

NASDAQ Market Internals

15:17
01/16/18
01/16
15:17
01/16/18
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

15:16
01/16/18
01/16
15:16
01/16/18
15:16
Technical Analysis
NYSE market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CLR

Continental Resources

$56.93

-0.73 (-1.27%)

15:15
01/16/18
01/16
15:15
01/16/18
15:15
Options
Continental Resources put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Jan

OLED

Universal Display

$196.60

-1.2 (-0.61%)

15:05
01/16/18
01/16
15:05
01/16/18
15:05
Options
Universal Display call volume above normal and directionally bullish »

Bullish option flow…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 17

    Jan

FRME

First Merchants

$44.20

0.31 (0.71%)

15:05
01/16/18
01/16
15:05
01/16/18
15:05
Hot Stocks
First Merchants announces company-wide raise, bonuses »

First Merchants announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jan

CEO

CNOOC

$159.15

-2.1 (-1.30%)

15:04
01/16/18
01/16
15:04
01/16/18
15:04
Downgrade
CNOOC rating change  »

CNOOC downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VRX

Valeant

$22.95

-0.8911 (-3.74%)

15:02
01/16/18
01/16
15:02
01/16/18
15:02
Recommendations
Valeant analyst commentary  »

Valeant settlement put…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 13

    Feb

  • 18

    Jun

  • 27

    Aug

UL

Unilever; also tag UN

$54.99

0.47 (0.86%)

, UN

Unilever; also tag UL

$56.07

0.575 (1.04%)

15:00
01/16/18
01/16
15:00
01/16/18
15:00
Conference/Events
Bernstein European HPC analyst holds an analyst/industry conference call »

European Food &…

UL

Unilever; also tag UN

$54.99

0.47 (0.86%)

UN

Unilever; also tag UL

$56.07

0.575 (1.04%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Feb

BTC

Bitcoin

, BITCOIN

Bitcoin

14:59
01/16/18
01/16
14:59
01/16/18
14:59
Hot Stocks
Crypto-currencies crash bringing related companies down with them »

Shares of…

BTC

Bitcoin

BITCOIN

Bitcoin

OSTK

Overstock.com

$78.95

-1.65 (-2.05%)

AMD

AMD

$12.02

-0.12 (-0.99%)

NVDA

Nvidia

$222.98

-1.1 (-0.49%)

SQ

Square

$38.71

-2.545 (-6.17%)

MARA

Marathon Patent Group

$4.17

0.33 (8.59%)

GBTC

Bitcoin Investment Trust

$1,970.00

261.995 (15.34%)

LBCC

Long Blockchain Corp.

$5.02

-0.48 (-8.73%)

KODK

Kodak

$8.38

-0.8249 (-8.97%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 26

    Jan

  • 30

    Jan

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.